Sarepta Therapeutics Inc $ 137.76 -6.2 (-4.31%)
Volume:
962,095
Avg Vol (1m):
743,149
Market Cap $:
10.81 Bil
Enterprise Value $:
9.52 Bil
P/E (TTM):
0.00
P/B:
10.37
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 2.69 | ||
| Equity-to-Asset | 0.36 | ||
| Debt-to-Equity | 0.74 | ||
| Debt-to-EBITDA | -1.69 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 2.97 | ||
| Beneish M-Score | -3.6 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -133.32 | ||
| Net Margin % | -117.8 | ||
| ROE % | -51.99 | ||
| ROA % | -23.88 | ||
| ROC (Joel Greenblatt) % | -189.06 | ||
| 3-Year Revenue Growth Rate | 259.9 | ||
| 3-Year EBITDA Growth Rate | -18.5 | ||
| 3-Year EPS without NRI Growth Rate | -20.9 |
SRPT
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Owner-Earnings | 47.94 | ||
| PB Ratio | 10.37 | ||
| PS Ratio | 23.24 | ||
| Price-to-Free-Cash-Flow | 46.5 | ||
| Price-to-Operating-Cash-Flow | 36.95 | ||
| EV-to-EBIT | -19.6 | ||
| EV-to-EBITDA | -20.97 | ||
| EV-to-Revenue | 21.14 | ||
| Current Ratio | 6.93 | ||
| Quick Ratio | 6.42 | ||
| Days Inventory | 1133.29 | ||
| Days Sales Outstanding | 76.77 | ||
| Days Payable | 613.12 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 10.49 | ||
| Price-to-Median-PS-Value | 0.75 | ||
| Earnings Yield (Greenblatt) % | -5.1 |